Whole exome sequencing (WES) is a powerful tool to investigate genetic variations underlying cancers, Mendelian diseases, and complex human disorders. Targeting only protein coding regions, WES provides a more cost-effective approach than whole genome sequencing.

As a CLIA-certified and CAP-accredited lab, Azenta Life Sciences, formerly GENEWIZ provides comprehensive solutions for exome sequencing at the research and clinical level.



Exome Sequencing Service Options

Exome Sequencing for Research Use Only

Our research-grade service provides customizable solutions for human and mouse exome sequencing. Flexible service packages are available to meet your budget and deadline requirements.

Clinical Exome Sequencing

Our clinical workflows are performed in a CLIA-certified lab by CLIA-trained personnel on CLIA-qualified equipment. Receive the highest level of regulatory compliance with our CLIA-validated clinical exome sequencing assay.

Verify your final targets of interest using Azenta’s confirmatory sequencing service.


Exome Sequencing Coverage For Any Application

  • 50x coverage

    (~5 Gb output)

    Germline variant discovery
    Uncovering disease-associated genotypes
  • 100x coverage

    (~10 Gb output)

    Somatic mutation discovery
    Tumor/normal sequencing
  • ≥200x coverage

    (20+ Gb output)

    Low frequency mutation detection
    Measuring tumor mutational burden (TMB)

Features & Benefits

Superior data quality with a guarantee of ≥80% bases with ≥Q30 for 2x150 bp sequencing (>90% on average)​
Multiple capture technologies available including Agilent SureSelect™ Human All Exon​
In-house pipeline for optional Sanger-based confirmatory sequencing of final targets utilizing your NGS samples
Dedicated support from Ph.D.-level project managers at every step including post-delivery support​
Complete sample-to-analysis solutions including flexible extraction and data analysis options available​
More reasons to choose Azenta

Exome Sequencing Workflow

1. Hybridization Capture

Fragment gDNA, bind probes to exons, and pull down

2. Library Preparation

Add adapters to exon-enriched DNA

3. Sequencing

Sequence 2x150 bp on Illumina® platform

4. Data Analysis

Identify SNVs, INDELs, gene fusions, and CNVs

Webinar| Non-Classical Sources of Tumour-Specific Antigen in Checkpoint Inhibitor Response

Developing immunotherapies for cancer can be difficult due to the variation of immune response from patient to patient. In this webinar, Dr. Litchfield from UCL Cancer Institute presents his team’s exploratory research using a multiomics approach to better understand the diversity of immune response to cancer and highlights their findings of an alternative source of a tumour-specific antigen in checkpoint inhibitor (CPI) response.

How To Order

Email | Phone 1-877-436-3949, Ext. 1